Several studies have shown that β-amyloid (βA) deposits are associated with damage of
cerebral vessels and that in Alzheimer's disease (AD) βA peptides are cytotoxic for cerebral …

The accumulation of amyloid-ß peptide (Aß) in the brain is a critical hallmark of Alzheimer's
disease. This high cerebral Aß concentration may be partly caused by impaired clearance of …

Findings from Alzheimer's disease (AD) mouse models showed that amylin treatment
improved AD pathology and enhanced amyloid-ß (Aß) brain to blood clearance; however …

Abstract Background/Aims: Alterations in the blood-brain barrier (BBB) may play an
important role in the pathogenesis and treatment of Alzheimer's disease (AD). We …

The blood–brain barrier (BBB) plays critical roles in the maintenance of central nervous
system (CNS) homeostasis. Dysfunction of the BBB occurs in a number of CNS diseases …

Impaired clearance in the Alzheimer's Disease (AD) brain is key in the formation of Aβ
parenchymal plaques and cerebrovascular deposits known as cerebral amyloid angiopathy …

Background Age is the major risk factor for many neurodegenerative diseases, including
Alzheimer's disease (AD). There is an accumulation of amyloid-beta peptides (Aβ) in both …

Amyloid plaques and neuronal loss with reactive gliosis are hallmarks of Alzheimer's
disease (AD). The amyloid deposits are composed of β-amyloid peptide (βA), which is …

Alzheimer's disease (AD) is a neurodegenerative disease, characterized histopathologically
by intra-neuronal tau-related lesions and by the accumulation of amyloid β-peptide (Aβ) in …

Vasoactive regulatory and transport proteins can modify the transendothelial blood-brain
barrier (BBB) transport of beta-amyloid. Dysfunction of one or more of these proteins is …